Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Danesi

Showing results (121-130 of 160) with videos related to

Pageof 16
Sort By:
European Journal of Clinical Investigation|August 19, 2007
In vitro antiangiogenic activity of selective somatostatin subtype-1 receptor agonistsG Bocci, M D Culler, A Fioravanti, et al.
Transplantation Proceedings|December 29, 2004
An exploratory study on pharmacogenetics of inosine-monophosphate dehydrogenase II in peripheral mononuclear cells from liver-transplant recipientsF Vannozzi, F Filipponi, A Di Paolo, et al.
British Journal of Cancer|July 27, 2006
In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patientsV Mey, E Giovannetti, F De Braud, et al.
Journal of Periodontology|January 28, 1998
Periodontal tissue disposition of azithromycinT Malizia, M R Tejada, E Ghelardi, et al.
Tumori|March 18, 1999
Suramin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in metastatic colorectal cancer patients resistant to 5-FU+LV-based chemotherapyA Falcone, E Pfanner, I Brunetti, et al.
Prostate Cancer and Prostatic Diseases|January 27, 2021
Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamideM Del Re, V Conteduca, S Crucitta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 1997
Maximum tolerable doses of intravenous zidovudine in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer patients. Clinical evidence of significant antitumor activity and enhancement of zidovudine-induced DNA single strand breaks in peripheral nuclear blood cellsA Falcone, M Lencioni, I Brunetti, et al.
Breast Cancer Research and Treatment|November 2, 2001
Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II studyP F Conte, A Gennari, S Donati, et al.
Journal of Environmental Radioactivity|December 26, 2002
Depleted uranium particles in selected Kosovo samplesP R Danesi, A Markowicz, E Chinea-Cano, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|June 3, 2021
What do we need to obtain high quality circulating tumor DNA (ctDNA) for routine diagnostic test in oncology? - Considerations on pre-analytical aspects by the IFCC workgroup cfDNAR Danesi, Y M D Lo, M Oellerich, et al.
Pageof 16

Showing results (121-130 of 160) with videos related to

Sort By:
Pageof 16
European Journal of Clinical Investigation|August 19, 2007
In vitro antiangiogenic activity of selective somatostatin subtype-1 receptor agonistsG Bocci, M D Culler, A Fioravanti, et al.
Transplantation Proceedings|December 29, 2004
An exploratory study on pharmacogenetics of inosine-monophosphate dehydrogenase II in peripheral mononuclear cells from liver-transplant recipientsF Vannozzi, F Filipponi, A Di Paolo, et al.
British Journal of Cancer|July 27, 2006
In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patientsV Mey, E Giovannetti, F De Braud, et al.
Journal of Periodontology|January 28, 1998
Periodontal tissue disposition of azithromycinT Malizia, M R Tejada, E Ghelardi, et al.
Tumori|March 18, 1999
Suramin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in metastatic colorectal cancer patients resistant to 5-FU+LV-based chemotherapyA Falcone, E Pfanner, I Brunetti, et al.
Prostate Cancer and Prostatic Diseases|January 27, 2021
Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamideM Del Re, V Conteduca, S Crucitta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 1997
Maximum tolerable doses of intravenous zidovudine in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer patients. Clinical evidence of significant antitumor activity and enhancement of zidovudine-induced DNA single strand breaks in peripheral nuclear blood cellsA Falcone, M Lencioni, I Brunetti, et al.
Breast Cancer Research and Treatment|November 2, 2001
Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II studyP F Conte, A Gennari, S Donati, et al.
Journal of Environmental Radioactivity|December 26, 2002
Depleted uranium particles in selected Kosovo samplesP R Danesi, A Markowicz, E Chinea-Cano, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|June 3, 2021
What do we need to obtain high quality circulating tumor DNA (ctDNA) for routine diagnostic test in oncology? - Considerations on pre-analytical aspects by the IFCC workgroup cfDNAR Danesi, Y M D Lo, M Oellerich, et al.
Pageof 16